trial · primary record
Rifaximin (drug)
Bloating
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 78 |
| Primary completion | 2028-12 |
| Primary endpoint | Bloating responder rate |
| Registry ID | NCT07522255 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:11.183Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07522255
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.